Business Wire

MERCK

Share
54% of Europeans Consider Their Current Physical Health to Be Good or Very Good, as Survey Reveals Public Perceptions of Health Following Nearly Two Years of the COVID-19 Pandemic

After two years of the Covid-19 pandemic, results from a European survey reveal that more than half of Europeans rate their physical health as good or very good - with a quarter of respondents reducing their alcohol and drug consumption and one in five saying they eat a healthier diet. Although 45% of Europeans rate their mental health as good or very good, 23% of the youngest (18-29 years old) say they have needed psychological help during the pandemic.

These are just some of the major findings from the "Merck Survey: Europeans' perception of health two years after the start of Covid 19" ; a survey of 6,000 people aged 18 to 65 from ten countries (Germany, Belgium, Spain, France, Italy, Poland, Portugal, United Kingdom, Czech Republic and Switzerland) that the science and technology company Merck carried out with the technical support of GAD3.

"This pandemic has triggered the biggest health, social and economic crisis in almost a century and - from the perspective of having overcome the most critical months of it - in Merck we wanted to know its impact on the health and lifestyle of Europeans,” says Marieta Jiménez, Senior Vice President of Merck Healthcare in Europe. " We believe that only by getting closer and asking people what they feel, think and need can we provide answers to the different health challenges. A healthy society is the basis for building a stronger, safer and more prosperous society," she adds.

The survey shows that Europeans (especially Italians, Spaniards and Portuguese) consider that the pandemic has helped them to talk openly in their personal and professional environment about their physical and mental health. In addition, one in three Europeans say that it has improved family coexistence and feelings of solidarity (34% and 33% respectively). Family co-existence was reported as a particular benefit by more Spaniards ad Czechs than in any other European country surveyed (42% and 45% respectively).

In contrast, the survey emphasizes the weight of emotional problems arising from the pandemic. The results show that 26% of all Europeans have developed a fear of physical contact with other people and 23% of young people surveyed have needed psychological help . Stress and anxiety, followed by fear and uncertainty, are the feelings that have affected more than a third of Europeans (38% and 33%, respectively).

When compared to the European average, stress and anxiety have affected countries such as Spain, Poland and Portugal more, while fear and uncertainty have particularly affected Spain, Italy and Portugal. Germany, Spain, the UK and Poland are the countries most affected by loneliness.

New times, new habits

The pandemic has also boosted the use of new health technologies. The Merck survey concludes that seven out of ten Europeans say they are comfortable or increasingly comfortable with telemedicine. Although most Europeans continue to prefer face-to-face consultations after the health crisis, people from Portugal, France and Italy reported a current preference for telemedicine vs. face-to-face consultations.

The survey further reveals that almost a quarter (24%) of Europeans say they have reduced their alcohol and drug consumption and one in five say they now eat a healthier diet.

Furthermore, only one in ten Europeans have postponed their plans to build or grow a family after the pandemic. People from the Czech Republic and Italy have postponed their intention to have children the most after the pandemic (14% and 15% respectively).

High recognition for health professionals

The study also probes opinions about the work of different health and science professionals during the pandemic. All countries recognize the good work of health personnel. In fact, 70% of Europeans rate the work of health workers and researchers as good or very good. Even so, it is worth noting that the performance of pharmacists during the pandemic was the most highly rated in all countries (compared to doctors, nurses, scientists and researchers) and they were the most highly rated in countries such as Spain and the Czech Republic.

When asked about what should be improved in the health system, 6 out of 10 European countries surveyed agree on the need to invest more in preventive medicine and public health, followed by primary care and mental health. Germans prefer researching new medicines over all other areas, while the British attach greater importance to mental health and the Poles call for greater primary care along with the Spanish.

Which diseases do Europeans fear the most?

In addition, the Merck Survey: Europeans' perception of health two years after the start of Covid 19” also points out that 75% of Europeans think that the health crisis has affected the normal course of cancer treatments. Cancer is the most feared disease in the wake of the pandemic, followed by neurodegenerative diseases, such as Alzheimer's or Parkinson's, and cardiovascular diseases.

“We are living unprecedented times and as a curious company we need to prioritize more than ever the value of science and professionals working in the service of health," emphasizes François Feig, Senior Vice President Mid Europe Healthcare at Merck. This ambitious survey sheds light on the feelings of Europeans about their health after two years of living with Covid and I believe that this information will allow all of us who put our efforts in the service of people's health and well-being to better understand their needs .

To access the Merck Survey, please follow this link .

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.

Link:

ClickThru

Social Media:

https://www.facebook.com/merckgroup/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye